PRA Health Sciences, Inc. (NASDAQ:PRAH) – Research analysts at KeyCorp cut their Q4 2017 earnings per share (EPS) estimates for PRA Health Sciences in a research note issued on Tuesday. KeyCorp analyst D. Hooker now expects that the medical research company will post earnings of $0.85 per share for the quarter, down from their previous forecast of $0.88.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Monday, August 7th. The medical research company reported $0.62 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.72 by $0.10. PRA Health Sciences had a return on equity of 21.17% and a net margin of 5.15%. The business had revenue of $457.90 million during the quarter, compared to the consensus estimate of $447.79 million. During the same quarter last year, the company earned $0.63 EPS. PRA Health Sciences’s revenue for the quarter was up .5% on a year-over-year basis.

ILLEGAL ACTIVITY NOTICE: “PRA Health Sciences, Inc. to Post Q4 2017 Earnings of $0.85 Per Share, KeyCorp Forecasts (PRAH)” was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/18/pra-health-sciences-inc-to-post-q4-2017-earnings-of-0-85-per-share-keycorp-forecasts-prah.html.

Several other equities research analysts have also commented on PRAH. SunTrust Banks, Inc. restated a “buy” rating on shares of PRA Health Sciences in a research report on Wednesday, August 9th. Citigroup Inc. restated a “buy” rating and issued a $93.00 price objective (up previously from $90.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. Credit Suisse Group upped their price objective on PRA Health Sciences from $80.00 to $84.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 8th. Robert W. Baird upped their price objective on PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 8th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $92.00 price objective (up previously from $88.00) on shares of PRA Health Sciences in a research report on Thursday, August 10th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $81.22.

Shares of PRA Health Sciences (PRAH) opened at 75.24 on Friday. The firm’s 50-day moving average is $75.24 and its 200-day moving average is $67.81. PRA Health Sciences has a 1-year low of $48.42 and a 1-year high of $80.99. The company has a market cap of $4.71 billion, a PE ratio of 48.57 and a beta of 0.45.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after buying an additional 160 shares during the last quarter. Meeder Asset Management Inc. increased its position in shares of PRA Health Sciences by 144.0% in the second quarter. Meeder Asset Management Inc. now owns 1,535 shares of the medical research company’s stock valued at $115,000 after buying an additional 906 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of PRA Health Sciences by 232.3% in the first quarter. Envestnet Asset Management Inc. now owns 1,844 shares of the medical research company’s stock valued at $121,000 after buying an additional 1,289 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new position in shares of PRA Health Sciences during the first quarter valued at $136,000. Finally, First Bank & Trust increased its position in shares of PRA Health Sciences by 1.7% in the first quarter. First Bank & Trust now owns 3,159 shares of the medical research company’s stock valued at $206,000 after buying an additional 54 shares during the last quarter. 96.76% of the stock is owned by institutional investors and hedge funds.

In other news, CEO Colin Shannon sold 400,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $74.85, for a total transaction of $29,940,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Pra Investors L.P. Kkr sold 9,500,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $74.85, for a total value of $711,075,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 10,000,000 shares of company stock worth $748,500,000. Insiders own 2.10% of the company’s stock.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.